In all, it is plausible that alterations in JNK and ERK signaling may constitute an important part of the mode-of-action of MAP4K4 in the control of NAFLD susceptibility. The gene discussed is MAP4K4; the disease is metabolic dysfunction-associated steatotic liver disease.